Investors - Press Releases
|View printer-friendly version|
Tabula Rasa HealthCare Supports Legislation to Establish Medication Risk Reduction Program for NJ Medicaid.
"The medication risk reduction model contemplated in the legislation closely mirrors TRHC's Enhanced Medication Therapy Management (EMTM) model," said
ADEs are "harms directly caused by a medication at normal doses." In the
Dr. Knowlton explained how TRHC's proprietary Medication Risk Mitigation technology, MedWise™, cumulatively compares how medications interact together and identifies medication-related risks. A TRHC published study involving nearly 2,000 patients found that a reduction in the MedWise Risk Score™ resulted in fewer adverse drug events, emergency department visits, and hospitalizations and in lower medical costs.
As with the
This press release includes forward-looking statements that we believe to be reasonable as of today's date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "should," and similar expressions. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the
TRHC Media Contact: Dianne Semingson, email@example.com, T: (215) 870-0829; TRHC Investor Contact: Frank Sparacino, firstname.lastname@example.org, T: (866) 648-2767